cd19-ucart

T-cell Leukemia

Beijing Boren HospitalCell therapyPhase 1Active

CCC

53/ 100

Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence: 39/ 100
Competitive Position: 95/ 100

Competitive context

3 Active assets in the T-cell Leukemia cohort.

Asset / Sponsor	Phase	Rating
METHOTREXATE Children's Oncology Group	Phase 2	B
(+)-VINCRISTINE Children's Oncology Group	Phase 2	B
Cyclophosphamide Xinqiao Hospital of Chongqing	Phase 2	B
PEGASPARGASE Children's Oncology Group	Phase 2	B
Cytosin-Arabinosid Children's Oncology Group	Phase 2	B

View all 29 →

Same molecule, other indications

cd19-ucart is also rated in:

B-Cell Acute Lymphoblastic Leukemia, AdultDormant

BBB

Indicative ·

72 / 100

B-cell non-Hodgkin lymphomaDormant

BB

Indicative ·

71 / 100

B-cell acute lymphoblastic leukemiaDormant

BB

Indicative ·

64 / 100

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.